Similar articles

• [After the early termination of the Women's Health Initiative study. New American recommendations for postmenopausal hormone therapy].

  Stjernquist M; North American Menopause Society (NAMS) Advisory Panel. Stjernquist M, et al. Lakartidningen. 2003 May 15;100(20):1790-7. Lakartidningen. 2003. PMID: 12806859 Swedish.
• [Health symptom-free women do not need preventive hormone replacement therapy. The risks outweigh the benefits; a large trial prematurely interrupted in the USA].

  von Schoultz B. von Schoultz B. Lakartidningen. 2002 Aug 22;99(34):3276-8. Lakartidningen. 2002. PMID: 12362844 Swedish. No abstract available.
• Good science or good marketing?

  Head K. Head K. Altern Med Rev. 2002 Aug;7(4):274-5. Altern Med Rev. 2002. PMID: 12197780 No abstract available.
• Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective.

  Randolph JF Jr; Women's Health Initiative Estrogen/Progestin and HERS II Trials. Randolph JF Jr, et al. Medscape Womens Health. 2002 Jul-Aug;7(4):7. Medscape Womens Health. 2002. PMID: 12466739 Review. No abstract available.
• Impact of WHI conclusions and ACOG guidelines on clinical practice.

  Gass M. Gass M. Int J Fertil Womens Med. 2003 May-Jun;48(3):106-10; discussion 137-8. Int J Fertil Womens Med. 2003. PMID: 12839140 Review.